CD80 and neoplasm: Possibly, the cause for this counterintuitive result lies in the interaction of CD80 with the inhibitory receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expressed on tumor infiltrating T cells, suggesting that co-treatment with CTLA-4 blocking agents could specifically boost antitumor immunity in this context.